Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073541 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer
A Phase 2 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00073541 is a Phase 2 study that has completed, run by EMD Serono. The registered enrollment target is 38 participants.
The verdict
NCT00073541, a Phase 2 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
EMD 72000 is an experimental, biological drug. Studies in animals indicate that EMD 72000 blocks a factor found on the surface of many cancer cells. The factor is called epidermal growth factor receptor or EGFR. One type of cancer which frequently contains EGFR is ovarian cancer. This study will test the safety and effects of EMD 72000 in subjects with EGFR-positive recurrent ovarian cancer following standard treatment that has failed.
Interventions
- DRUG EMD 72000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2003-04 |
| Est. Completion | 2004-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073541
The ClinicalTrials.gov registry entry for NCT00073541 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EMD 72000 is the first listed.
NCT00073541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073541 about?
NCT00073541 is a clinical study titled "A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer". EMD 72000 is an experimental, biological drug. Studies in animals indicate that EMD 72000 blocks a factor found on the surface of many cancer cells. The factor is called epidermal growth factor receptor or EGFR. One type of cancer which frequently contains EGFR is ovarian cancer. This study will tes...
What is the current status of trial NCT00073541?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2003-04. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00073541?
The interventions under investigation include: EMD 72000 (DRUG).
Who is sponsoring clinical trial NCT00073541?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.